Top Guns: The "maverick" and "goose" of Empiric Therapy

Surgical Infections

Volumn 17, Issue 1, 2016, Pages 38-47

  Davies, Stephen W ^a   Efird, Jimmy T ^b   Guidry, Christopher A ^a   Dietch, Zachary C ^a   Willis, Rhett N ^a   Shah, Puja M ^a   Sawyer, Robert G ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN; ANTIINFECTIVE AGENT; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

ADULT; AGE; AGED; ANTIBIOTIC THERAPY; APACHE; ARTICLE; BLOOD TRANSFUSION; BLOODSTREAM INFECTION; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; ENTEROBACTER CLOACAE; FEMALE; HOSPITAL INFECTION; HUMAN; INFECTION; INJURY; INTESTINE INFECTION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PERITONITIS; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; SKIN INFECTION; SURGICAL INFECTION; TREATMENT OUTCOME; VANCOMYCIN RESISTANT ENTEROCOCCUS; ANALOGS AND DERIVATIVES; ANIMAL; BACTERIAL INFECTIONS; CHEMICALLY INDUCED; CRITICAL ILLNESS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; MIDDLE AGED; RENAL INSUFFICIENCY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CRITICAL ILLNESS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; VANCOMYCIN;

EID: 84955257070     PISSN: 10962964     EISSN: 15578674     Source Type: Journal    
DOI: 10.1089/sur.2015.104     Document Type: Article

References (34)

1. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41: 580-637.
2. Marie JP, Marjanovic Z, Vekhoff A, et al. Piperacillin/ tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for fever in severely neutropenic patients. Supportive Care Cancer 1999;7:89-94.
3. Bassetti M, Righi E. Multidrug-resistant bacteria: What is the threat? Hematology 2013;2013:428-432.
4. Vazquez-Guillamet C, ScolariM, ZilberbergMD, et al. Using the number needed to treat to assess appropriate antimicrobial therapy as a determinant of outcome in severe sepsis and septic shock. Critical Care Med 2014;42:2342-2349.
5. Rodriguez-Bano J. Selection of empiric therapy in patients with catheter-related infections. Clin Microbiol Infect 2002; 8:275-281.
6. Williams ME, Harman C, Scheld M, et al. A controlled study of ticarcillin plus clavulanic acid versus piperacillin as empiric therapy for fever in the immunocompromised host. Am J Med 1985;79:67-72.
7. Wang LS, Liu CY, Wang FD, et al. Chromatographically purified vancomycin: Therapy of serious infections caused by Staphylococcus aureus and other gram-positive bacteria. Clin Ther 1988;10:574-584.
8. Goren MP, Baker DK Jr, Shenep JL. Vancomycin does not enhance amikacin-induced tubular nephrotoxicity in children. Pediatr Infect Dis J 1989;8:278-282.
9. Wong-Beringer A, Joo J, Tse E, Beringer P. Vancomycinassociated nephrotoxicity: A critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents 2011;37:95-101.
10. Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycin-associated nephrotoxicity: Grave concern or death by character assassination? Am J Med 2010;123: 182. e1-7.
11. Menichetti F, Martino P, Bucaneve G, et al. Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program. Antimicrob Agents Chemother 1994;38:2041-2046.
12. Pletz MW, Burkhardt O, Welte T. Nosocomial methicillinresistant Staphylococcus aureus (MRSA) pneumonia: Linezolid or vancomycin? Comparison of pharmacology and clinical efficacy. Eur J Med Res 2010;15:507-513.
13. Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A. Vancomycin-induced nephrotoxicity: Mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol 2012;68:1243-1255.
14. Bosso JA, Nappi J, Rudisill C, et al. Relationship between vancomycin trough concentrations and nephrotoxicity: A prospective multicenter trial. Antimicrob Agents Chemother 2011;55:5475-5479.
15. Kureishi A, Jewesson PJ, Rubinger M, et al. Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: Effect on cyclosporin A-associated nephrotoxicity. Antimicrob Agents Chemother 1991;35:2246-2252.
16. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrobial Agents Chemother 2008;52:1330-1336.
17. Cohen E, Dadashev A, Drucker M, et al. Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patients. J Antimicrob Chemother 2002;49:155-160.
18. Cano EL, Haque NZ, Welch VL, et al. Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: Retrospective analysis of the IMPACT-HAP Database. Clin Ther 2012;34:149-157.
19. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: A randomized, controlled study. Clin Infect Dis 2012;54:621-629.
20. Davies SW, Guidry CA, Petroze RT, et al. Vancomycin and nephrotoxicity: just another myth? J Trauma Acute Care Surg 2013;75:830-835.
21. Burgess LD, Drew RH. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy 2014;34:670-676.
22. Gomes DM, Smotherman C, Birch A, et al. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. Pharmacotherapy 2014;34:662-669.
23. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309-332.
24. Jeffres MN, Isakow W, Doherty JA, et al. A retrospective analysis of possible renal toxicity associatedwith vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007;29:1107-1115.
25. Pan W. Akaike's information criterion in generalized estimating equations. Biometrics 2001;57:120-125.
26. Huber PJ (ed). The Behavior of Maximum Likelihood Estimates Under Nonstandard Conditions. Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability. Berkeley, CA: University of California Press, 1967.
27. Dilworth TJ, Sliwinski J, Ryan K, et al. Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus isolates and vancomycin-intermediate S. Aureus isolates in vitro. Antimicrob Agents Chemother 2014;58:1028-1033.
28. Vandecasteele SJ, De Vriese AS, Tacconelli E. The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: Evidence and uncertainties. J Antimicrob Chemother 2013;68:743-748.
29. Martin JH, Norris R, BarrasM, et al. Therapeuticmonitoring of vancomycin in adult patients: A consensus review of the American Society ofHealth-SystemPharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists. Clin Biochem Rev 2010;31:21-24.
30. Mah GT, Mabasa VH, Chow I, Ensom MH. Evaluating outcomes associated with alternative dosing strategies for piperacillin/tazobactam: A qualitative systematic review. Ann Pharmacother 2012;46:265-275.
31. Pratt JA, Stricherz MK, Verghese PS, Burke MJ. Suspected piperacillin-tazobactam induced nephrotoxicity in the pediatric oncology population. Pediatr Blood Cancer 2014;61: 366-368.
32. Pill MW, O'Neill CV, Chapman MM, Singh AK. Suspected acute interstitial nephritis induced by piperacillintazobactam. Pharmacotherapy 1997;17:166-169.
33. Moenster RP, Linneman TW, Finnegan PM, et al. Acute renal failure associated with vancomycin and beta-lactams for the treatment of osteomyelitis in diabetics: Piperacillintazobactam as compared with cefepime. Clin Microbiol Infect 2014;20:O384-389.
34. Jensen JU, Hein L, Lundgren B, et al. Kidney failure related to broad-spectrum antibiotics in critically ill patients: Secondary end point results from a 1200 patient randomised trial. BMJ Open 2012;2:e000635.